J&J's CFO Says Company Is 'Leaning Towards A Spin' Of DePuy Synthes, Targets Mid-2027

The finance chief favored a spin-off of the orthopedics unit as MedTech sales rose 2.5%, a result its chief said missed J&J's own standard.

Share
J&J's CFO Says Company Is 'Leaning Towards A Spin' Of DePuy Synthes, Targets Mid-2027

Johnson & Johnson Chief Financial Officer Joe Wolk said on the company's third-quarter earnings call that J&J is "leaning towards a spin" of its DePuy Synthes orthopedics business, with separation still planned by mid-2027. The same call carried a blunt admission from MedTech chief Tim Schmid that MedTech sales growth of 2.5% fell short of what investors had been told to expect.

Spin favored for DePuy Synthes

Wolk said the company has evaluated every separation vehicle and that all options are better positioned today than when J&J announced its intentions. Given how DePuy Synthes is performing, he said, "we are leaning towards a spin as being the best option to create long-term value for Johnson & Johnson shareholders."

He added that a spin "has always been our base plan." The Wall Street Journal reported that J&J had talked with private-equity firm Apollo Global Management about a roughly $20 billion sale of the unit before shifting toward a spin.

Wolk said further updates will come when there is more to share.

MedTech misses its own bar

Schmid, executive vice president and worldwide chairman of MedTech, told a Citi analyst that performance was "below the standard we have set internally" and below expectations previously communicated to investors. "We can do better and we absolutely will," he said.

MedTech sales were $8.6 billion, up 2.5%, with the U.S. up 4.8% and sales outside the U.S. up 0.1%. Surgery fell 1%. Abiomed, the heart-pump business, fell 1.5% on lower patient volume, per the call transcript. Schmid pointed to two pressure points: markets outside the U.S., and Abiomed worldwide. He also cited a broadening Middle East conflict that disrupted ordering and tender timing.

Orthopedics grew 3.4% in the quarter. Total company sales were $25.4 billion, up 6%, and J&J raised its 2026 operational sales growth guidance to 6.7% to 7.1%.

The 2027 math and what comes next

Wolk said Firefly Bio and SAIL Biomedicines will together dilute 2027 adjusted earnings per share by $1.36, versus $0.64 this year. In Tuesday trading, as of 10:05 a.m. ET, J&J shares were down 5.02% at $250.49 from a prior close of $263.73.

J&J will give its 2027 outlook at an enterprise business review on December 8, Wolk said, including a pro forma view reflecting the orthopedic separation should it occur.

The December 8 review is where J&J has said it will put numbers on 2027, with and without DePuy Synthes.

Sources

More on Johnson & Johnson

All Johnson & Johnson (JNJ) coverage →